Onconetix, Inc.

Contributing Author

Recent Articles by Onconetix, Inc.

Sep-26	Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc. ONCO GlobeNewswire
Sep-26	Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement ONCO GlobeNewswire
Sep-22	Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM ONCO GlobeNewswire
Jul-16	Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement ONCO GlobeNewswire
Jun-16	Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel ONCO GlobeNewswire
Jun-11	Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders ONCO GlobeNewswire
May-22	Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq ONCO GlobeNewswire